Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors
🌟 Latest Breakthrough: Chinese Biotech Company Achieves Milestone with Targeted CT041 CAR-T Therapy in Treating Gastrointestinal Tumors 🌟
Gastrointestinal Tumor
Chinese biotech company CARsgen Therapeutics unveiled the latest data for its targeted Claudin18.2 autologous CAR-T cell candidate product, CT041, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This therapy is specifically designed for Claudin18.2-positive solid tumors, such as gastric cancer, gastroesophageal junction adenocarcinoma, and pancreatic cancer.
🔬 **About CT041**
CT041 (satricabtagene autoleucel, satri-cel) is a groundbreaking CAR-T cell therapy undergoing multiple clinical trials in both China and the United States. Since 2022, it has received RMAT designation and orphan drug status from the FDA, and PRIME designation from the EMA.
📊 **Clinical Trial Highlights**
Between March 2019 and January 2024, a total of 98 patients participated in the Phase 1 trial of CT041. The trial results indicated:
– **Safety**: The most common adverse events were hematologic toxicities related to lymphocyte depletion, with no dose-limiting toxicities or treatment-related deaths reported.
– **Efficacy**: The overall objective response rate (ORR) was 37.8%, and the disease control rate (DCR) was 75.5%. The median progression-free survival (PFS) was 4.4 months, and the median overall survival (OS) was 8.4 months.
For gastric cancer patients, the results were even more remarkable:
– **ORR**: 57.4%
– **DCR**: 83.0%
– **Median PFS**: 5.8 months
– **Median OS**: 9.7 months
🎯 **Future Outlook**
CT041 has demonstrated promising safety and highly encouraging efficacy in heavily pretreated Claudin18.2-positive advanced gastrointestinal cancer patients. This breakthrough brings new hope and treatment options for patients with gastrointestinal tumors.
Follow us for more updates on the latest medical breakthroughs! 💡🌐
Whatsapp：+8613717959070
Email: doctor.huang@globecancer.com
#MedicalBreakthrough #CancerTreatment #CAR_T #CT041 #GastricCancer #PancreaticCancer #CARsgenTherapeutics #ASCO2024 #MedicalAdvances #CARsgen
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
$160,000 per dose! The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.
🌈 $160,000 per dose! 🌈
⭐The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.
multiple myeloma
Zevor-cel
🌦On March 5th, the fifth approved CAR-T therapy in China, Zevor-cel injection (Zevor-cel) by CARsgen, was priced at $116,000 for its initial release.
Zevor-cel injection is an autologous CAR-T product targeting BCMA. It is the fifth CAR-T therapy approved and marketed in China, following Axicabtagene Ciloleucel by Fosun Kite, Relmacabtagene Autoleucel by JW Therapeutics, Equecabtagene Autoleucel by IASO Bio, and Inaticabtagene Autoleucel by Juventas.
Cheapest CAR-T therapy
🌺Currently, the cheapest approved CAR-T therapy in the world is Inaticabtagene Autoleucel by Juventas. The price has dropped below one million RMB, at 999,000 RMB (equivalent to less than $140,000).
US CAR-T
🌼In 2017, the US FDA approved two CAR-T products, marking the beginning of the era of immunocellular therapy. CAR-T therapy has always been known for its high prices. Just how expensive is it? The two CAR-T therapies approved for sale in the United States are priced at $475,000 (Kymriah) and $373,000 (Yescarta), and these are just the prices of the drugs themselves. The total cost of the treatment far exceeds these amounts.
Multiple Myeloma
🌻For the treatment of multiple myeloma, there are currently two CAR-T products on the US market: Idecabtagene vicleucel by BMS/bluebird bio and ciltacabtagene autoleucel by Legend Bio. They are priced at $419,000 and $465,000, respectively, with a BCMA target and a complete response (CR) rate of 28% and 78%.
In China
⚡ there are also two CAR-T products on the market: Zevor-cel injection by CARsgen and Equecabtagene Autoleucel injection by IASO Bio. They are priced at $160,000 and $162,000, respectively, with the same BCMA target and CR rates as high as 78.6% and 82.4%.
🌤To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp+8613717959070
doctor.huang@globecancer.com
#CARTtherapy #CancerTreatment #Immunotherapy #MultipleMyeloma #BCMA #Zevorcel #CARsgen #MedicalBreakthrough #HealthcareInnovation #PrecisionMedicine #PersonalizedMedicine #MedicalAdvancements #FightAgainstCancer #GlobalHealthcare #AffordableMedicine
#CancerResearch #PatientCare #MedicalTechnology #InnovativeTherapy #HopeForPatients
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%!
✨ The domestically researched CAR-T therapy in China significantly increases the remission rate of multiple myeloma patients, with the highest reaching up to 100%! ✨
multiple myeloma
🌟BCMA (also known as CD269) and GPRC5D, these two targets are revolutionizing the treatment landscape of multiple myeloma (MM). BCMA is one of the hottest targets for treating MM currently, while GPRC5D is poised to be a potent complement to BCMA.
🔍 About BCMA: CAR-T Therapy with Remission Rates Exceeding 90%!
👩⚕️BCMA is primarily expressed on the surface of terminally differentiated B cells, making it a promising new target in hematologic malignancies treatment. Currently, both in clinical trials and marketed BCMA-targeted CAR-T therapies have shown significant efficacy, with some second-generation CAR-T projects achieving remission rates of over 90%, and the remission rates of domestically produced CAR-T products are also leading globally.
Among domestically produced CAR-T therapies in China,
🌟The marketed injection of Cilta-cel (Carvykti) has an overall remission rate of 89.6% and a complete remission rate of 77.1%.
🌟The fully human Equecabtagene Autoleucel injection (developed by the highly regarded Chinese company IASO Bio) boasts an overall remission rate of 98.9%, with a complete remission rate of 82.4%.
🌟Additionally, recent follow-up data from the ASH conference showed that Zevor-cel, developed by Chinese company CARsgen and just approved for market in China, has an overall remission rate of 100%, with a complete remission rate of 92.9%.
💡 About GPRC5D: A New Hopeful Treatment Target!
🔬About 65% of MM patients exhibit high expression of GPRC5D, and its expression is relatively independent of BCMA. The development speed of domestically produced CAR-T projects in China is considerable. For example, OriCAR-017, a CAR-T product developed by a domestic pharmaceutical company, achieved an overall remission rate of 100% in 10 trial patients, with a strict complete remission rate of 60%.
🩺China is rapidly advancing in the field of CAR-T therapy, leading the way in both technological development and clinical applications. In the future, we will witness more “miracles of healing” created by these novel cell therapies.
We can help all international patients come to China to receive anticancer therapies such as CAR-T, TILs, and cancer vaccines.
We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.
doctor.huang@globecancer.com
WhatsApp+8613717959070
#MultipleMyeloma #BCMA #GPRC5D #CART #CellTherapy #MiraclesOfHealing #CARTcell
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Breaking News Alert! Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China!
🚀 Breaking News Alert! 🚀
🎉 Exciting news for multiple myeloma patients! A groundbreaking CAR-T therapy has been approved for launch in China! 🎉
multiple myeloma
CARsgen
🔍On March 1st, 2024, CARsgen, a leading Chinese pharmaceutical company, proudly announced the official approval by the National Medical Products Administration (NMPA) of their innovative CAR-T cell immunotherapy product, Zevor-cel, targeting BCMA. This revolutionary treatment is specifically designed for adult patients with relapsed or refractory multiple myeloma who have undergone at least three prior lines of treatment, including a proteasome inhibitor and an immunomodulatory agent.
Zevor-cel
🌟 Zevor-cel marks CARsgen’s debut commercial product, promising a new ray of hope for patients. While the price remains undisclosed, anticipation is high as it is expected to be competitive with its counterparts. Stay tuned as we eagerly await the reveal of its pricing strategy!
💪At the 2023 ASH Annual Meeting, Zevor-cel’s impressive three-year follow-up data stole the spotlight, boasting a remarkable Overall Response Rate (ORR) of 100% and a median Progression-Free Survival (PFS) of 25.0 months. With a median Overall Survival (OS) yet to be reached, the two-year OS rate has already hit 100%, and the three-year OS rate stands at a remarkable 92.9%, underscoring its outstanding safety profile and offering renewed hope for patients battling relapsed or refractory multiple myeloma.
Multiple Myeloma
👍In terms of approved indications, it’s worth noting that the current portfolio of domestic CAR-T therapies in China caters to various hematologic malignancies. While FOSUNKITE and JW Therapeutics target lymphomas, JUVENTAS focuses on leukemia. CARsgen and IASO Bio, however, have set their sights on multiple myeloma, aligning perfectly with the pressing medical needs of patients in this category.
👏Let’s celebrate this remarkable milestone in the fight against multiple myeloma, as we continue to strive for better, more effective treatments to improve patients’ lives worldwide! 🌍 #TogetherWeCanBeatCancer
If you are interested in the latest cancer-fighting technologies and treatment methods in China, or if any of patients wish to learn more, our team is available to support and advise you and your patients at any time.
Website：[https://www.medtourcn.com/]
Whatsapp：+8613717959070
Email: doctor.huang@globecancer.com
🔍 #Zevorcel #CARsgen #MultipleMyeloma #CARTTherapy #MedicalBreakthrough #NMPAApproval #HopeForPatients #HealthcareInnovation #CancerTreatment #MedicalAdvancement